Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. surgery radiation
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Surgery Radiation Articles & Analysis

30 news found

Bayer expands global clinical program for darolutamide in prostate cancer

Bayer expands global clinical program for darolutamide in prostate cancer

BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well as metastatic ...

ByBayer AG


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.7 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

New data presented at ASCO GU confirm survival benefits and favorable safety profile of darolutamide across different subgroups of patients with metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.80F[i] At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.6 At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasize or spread, or if the ...

ByBayer AG


GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

Standard treatment options for RCC are surgery, radiation, chemotherapy, targeted therapy or immunotherapy. ...

ByGeneCentric Therapeutics, Inc.


Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial

Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial

The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. It is being conducted at three leading canine oncology centers – the Flint Animal Cancer Center at Colorado State University, the School of Veterinary Medicine at University of Wisconsin-Madison and the University of ...

ByCalviri


PreludeDx to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT During Oral Presentation at ASCO 2022 Annual Meeting

PreludeDx to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT During Oral Presentation at ASCO 2022 Annual Meeting

The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...

ByPreludeDx


PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT

The study included 493 patients from three cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT). DCISionRT and its RRt classified patients into Low, Elevated and Residual Risk groups with the Residual Risk group having the highest 10-year ipsilateral breast recurrence (IBR) risk without RT and significantly elevated IBR ...

ByPreludeDx


Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

Bayer raises peak sales for Nubeqa to exceed three billion euro amid positive Phase III ARASENS trial data

In addition, a study to explore the potential of darolutamide in the early setting for patients who have been treated with surgery or radiation and now see a rise in their prostate specific antigen (PSA) levels is also planned. ...

ByBayer AG


Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System

Augmedics Secures $8.3 Million in Series A Funding for Augmented-Reality Surgical Visualization System

With The ViZOR, surgeons can see inside a patient’s anatomy through skin and tissue, for easier, faster and safer surgeries. The ViZOR can be used in many procedures, with the first intended use in minimally invasive spine surgeries. ...

ByAugmedics


New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed’s L-Dex® Technology and Intervention

When looking at key risk factors for BCRL, including body weight, stage of cancer, type of cancer surgery, lymph node dissection, chemotherapy, and radiation, the benefit of using L-Dex monitoring was consistent and showed the utility of L-Dex across a large group of breast cancer ...

ByImpediMed Inc.


GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

GammaTile Therapy Delivers Targeted Radiation to Cancer Cells

They are implanted by the surgeon and deliver ninety percent of the radiation dose in 33 days. After 100 days, the GammaTile radiation sources are exhausted, and the collagen tiles disintegrate. ...

ByGT Medical Technologies, Inc.


Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems

Orthofix Announces Investment and Partnership with nView medical, Developer of Novel Imaging and Guidance Systems

Food and Drug Administration 510(k) cleared imaging system that features the unique ability to instantly capture 3D images with very low-dose radiation. This approach makes the 3D images available throughout surgery, enabling real time visualization. ...

BynView medical Inc.


Study Demonstrate Superiority of VeraForm® Marker Over Clips

Study Demonstrate Superiority of VeraForm® Marker Over Clips

“Clear targeting of the tumor bed is essential for radiation therapy”, stated the lead author and radiation oncologist, Jaroslaw Hepel M.D., Director of Stereotactic Radiosurgery at Rhode Island Hospital and Associate Professor of Radiation Oncology at The Warren Alpert Medical School of Brown University. ...

ByVidera Surgical Inc.


Beyond Death Valley: Medtech Veteran Breathes New Life into HIFU Company

Beyond Death Valley: Medtech Veteran Breathes New Life into HIFU Company

He compares HIFU to the early days of robotic surgery: “The HIFU market is still in its infancy, and Rhodes said it reminds him of his early days at Intuitive Surgical, when the Irvine, CA-based robotics company was focused on prostate cancer, specifically radical prostatectomy, which was also a very young market at the ...

ByEDAP TMS


Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation

Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation

The center offers the latest and most advanced diagnostics and treatments in surgery, chemotherapy, and radiation therapy. It attains its mission through an innovative study of cancer, thoughtful and compassionate care, specialized treatment options, and procedures. ...

ByCalviri


New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers

New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers

MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation ...

ByMiraDx


University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors

University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors

"GammaTile has the potential to allow patients to have their radiation and surgery simultaneously, allowing patients to get back to their families and their lives several months earlier than with other methods," said Dr. ...

ByGT Medical Technologies, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT